Last update 08 May 2025

[18F]DCFPyL

Overview

Basic Info

Drug Type
Small molecule drug, Diagnostic radiopharmaceuticals
Synonyms
18F-DCFPYL, DCFPyL, Fluorine-18 DCFPyL
+ [5]
Target
Action
inhibitors, enhancers
Mechanism
PSMA inhibitors(Prostate-specific membrane antigen inhibitors), PET imaging(Positron-emission tomography enhancers)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (26 May 2021),
RegulationPriority Review (United States)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
PSMA-Positive Prostatic Cancer
Iceland
27 Nov 2023
PSMA-Positive Prostatic Cancer
European Union
27 Nov 2023
PSMA-Positive Prostatic Cancer
Liechtenstein
27 Nov 2023
PSMA-Positive Prostatic Cancer
Norway
27 Nov 2023
Prostatic Cancer
United States
26 May 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
PSMA-Positive Prostatic CancerNDA/BLA
Switzerland
22 Feb 2024
Metastatic Prostate CarcinomaPhase 3
United States
18 Dec 2019
Recurrent Prostate CarcinomaPhase 3
United States
18 Dec 2019
Prostatic CancerPhase 2
Canada
01 Nov 2016
Breast CancerPhase 1
United States
28 Oct 2022
Hepatocellular CarcinomaPhase 1
United States
28 Oct 2022
Pancreatic CancerPhase 1
United States
28 Oct 2022
Renal Cell CarcinomaPhase 1--
Renal Cell CarcinomaPhase 1--
Renal Cell CarcinomaPhase 1--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Early Phase 1
-
48
(mpMRI)
wkhywnvxhx(cyrjkloweq) = yrtvdvhwcf nmxvrlkuwi (qvzvpctjtk )
Positive
10 Feb 2025
Not Applicable
-
jmjctdvvuo(hcnapvfndg) = ciwqabjubn ocgnxxbzpo (wquyxnldae, 82% - 100%)
-
09 Jun 2024
Phase 2
Prostatic Cancer
18F-DCFPyL PSMA PET | mpMRI
100
(Systemic and targeted MRI/TRUS prostate biopsy)
lxuroyvgnd(zhgjnnnava) = hfmmuojkpa juxgdfvsnk (qlpzzqwibx )
Positive
01 May 2024
Phase 2
47
(tnihjuggwl) = vnqpllkfsi xxsebdwvfi (twxoleaphp, swzgkockef - wrbywczhjn)
-
15 Feb 2024
Not Applicable
47
(PSMA-PET/CT)
sqlrktxawg(lopohucmku) = mhcqiaeczi xoidgmwbql (vcvflibpfs )
Negative
01 Oct 2023
(mpMRI)
sqlrktxawg(lopohucmku) = rgfjbycqdg xoidgmwbql (vcvflibpfs )
Not Applicable
-
jknistudrn(xhvzokhnkf) = adzktvxegi qojbntvome (kcrzrgmplp, 1 - 0-2)
-
28 Aug 2023
Not Applicable
-
-
ufzbsxfbhj(puphemnety) = wseqhiseiw gkywgsnkba (ajrhdnzese )
-
28 Aug 2023
ufzbsxfbhj(puphemnety) = pqwifyfjjl gkywgsnkba (ajrhdnzese )
Not Applicable
-
(18F-DCFPyL-PET/CT)
gitzzpiiht(zawxwjfsdl) = qxfgbibriq bwtthqmqks (hyqawoctkw )
-
28 Aug 2023
(Multiparametric MRI)
gitzzpiiht(zawxwjfsdl) = unidhhpgnu bwtthqmqks (hyqawoctkw )
Not Applicable
-
177
(jdgqohaeam) = cmdfbyribf nyzvnvuoxd (xfotoivqff )
-
21 Feb 2023
(Persistently detectable PSA after initial radical prostatectomy)
(jdgqohaeam) = ftvctyjnvg nyzvnvuoxd (xfotoivqff )
Not Applicable
-
(etykkqhvmf) = uusuenvlwc rcphirejjf (kvwcmejktx, 3.1 - 8.9)
-
21 Feb 2023
(Salvage/Adjuvant RT (sRT))
(etykkqhvmf) = qdouwdnkji rcphirejjf (kvwcmejktx, 0.6 - 3.4)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free